Our results obtained for the conjugate PAMAM–dox–trastuzumab showed an increase in the toxic efficiency towards HER-2 positive human breast cancer cells compared to the free drug or the conjugate PAMAM–trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.